Coherus Biosciences Inc - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
CHRS Nasdaq 2833 https://www.coherus.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Coherus Biosciences Inc

Coherus BioSciences Announces New Employment Inducement Grants - Feb 3rd, 2023 10:30 pm
'Go big or go home': How a Peninsula biotech looks to win in Humira biosimilar 'feeding frenzy' - Jan 30th, 2023 10:57 pm
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma - Jan 9th, 2023 1:20 pm
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 4th, 2023 12:01 pm
Should You Invest in Coherus BioSciences (CHRS)? - Jan 3rd, 2023 12:12 pm
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) - Dec 25th, 2022 1:16 pm
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) - Dec 24th, 2022 5:01 am
With 74% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns - Dec 21st, 2022 11:52 am
Coherus BioSciences Third Quarter 2022 Earnings: Misses Expectations - Nov 10th, 2022 11:18 am
Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates - Nov 8th, 2022 10:25 pm
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update - Nov 8th, 2022 9:01 pm
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022 - Nov 1st, 2022 11:30 am
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 55% over the last three years - Oct 18th, 2022 2:48 pm
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology - Oct 12th, 2022 11:30 am
Will Coherus BioSciences (CHRS) Stock Bounce Back? - Oct 10th, 2022 3:49 pm
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 - Sep 19th, 2022 11:30 am
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference - Sep 12th, 2022 12:30 pm
Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing - Sep 2nd, 2022 1:55 pm
Wall Street Analysts Think Coherus BioSciences (CHRS) Could Surge 47%: Read This Before Placing a Bet - Aug 19th, 2022 1:55 pm
Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript - Aug 6th, 2022 9:00 am